Recent Updates
Recently added Catalysts
HROW Positive Sentiment

Harrow to Participate in Two Investor Conferences in November

Key Takeaway: Harrow (Nasdaq: HROW) announced its participation in two investor conferences in November 2026. The Craig-Hallum 17th Annual Alpha Select Conference will be held on November 17, while the Jefferies Global Healthcare Conference is scheduled for November 18. The latter will include a live webcast accessible on the company's website.
Price reaction · baseline $29.37 (2026-11-11 close) · hit pre-market · clean, no other HROW news in the window
day 0 close · peak
-3.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in two notable investor conferences
  • Opportunity for 1x1 meetings with management
  • Live webcast of the Jefferies presentation

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+67%
120-day peak, hindsight
Typical move
9.5%
average across 5 past catalysts
Cash runway
~26 mo
Minimal dilution risk
Lead asset
TRIESENCE
Phase 3 · Postoperative Ocular Inflammation

Full Press Release Details

NASHVILLE, Tenn., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following investor conferences in November:

Craig-Hallum 17th Annual Alpha Select Conference

• Format: 1x1 investor meetings
• Date: Tuesday, November 17, 2026
• Location: New York, NY

2026 Jefferies Global Healthcare Conference

• Format: Presentation and 1x1 investor meetings
• Date/Time: Wednesday, November 18, 2026 at 8:00 a.m. GMT (3:00 a.m. ET)
• Location: London, UK
The Jefferies presentation will be webcast live and can be accessed on the Events page of the Company’s website. A replay of the webcast will be available for approximately 90 days following the presentation. Investors interested in meeting with management during either of these conferences should contact their representative at the sponsoring firm to request a meeting.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Contact: Mike Biega Vice President of Investor Relations and Communications mbiega@harrowinc.com 617-913-8890

Frequently Asked Questions

When will Harrow participate in the investor conferences?

Harrow will participate on November 17 and 18, 2026.

Where will the conferences be held?

The conferences will take place in New York, NY, and London, UK.

Will the Jefferies presentation be available online?

Yes, the Jefferies presentation will be webcast live.

How can investors meet with Harrow's management?

Investors should contact their representative at the sponsoring firm.

Last updated: Nov 12, 2026